IBDEI10J ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16475,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,16475,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,16475,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,16476,0)
 ;;=C92.40^^61^775^20
 ;;^UTILITY(U,$J,358.3,16476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16476,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,16476,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,16476,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,16477,0)
 ;;=D56.0^^61^775^21
 ;;^UTILITY(U,$J,358.3,16477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16477,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,16477,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,16477,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,16478,0)
 ;;=D63.1^^61^775^23
 ;;^UTILITY(U,$J,358.3,16478,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16478,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,16478,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,16478,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,16479,0)
 ;;=D63.0^^61^775^24
 ;;^UTILITY(U,$J,358.3,16479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16479,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,16479,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,16479,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,16480,0)
 ;;=D63.8^^61^775^22
 ;;^UTILITY(U,$J,358.3,16480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16480,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,16480,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,16480,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,16481,0)
 ;;=C22.3^^61^775^27
 ;;^UTILITY(U,$J,358.3,16481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16481,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,16481,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,16481,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,16482,0)
 ;;=D61.9^^61^775^28
 ;;^UTILITY(U,$J,358.3,16482,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16482,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,16482,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,16482,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,16483,0)
 ;;=D56.1^^61^775^34
 ;;^UTILITY(U,$J,358.3,16483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16483,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,16483,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,16483,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,16484,0)
 ;;=C83.79^^61^775^36
 ;;^UTILITY(U,$J,358.3,16484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16484,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16484,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,16484,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,16485,0)
 ;;=C83.70^^61^775^37
 ;;^UTILITY(U,$J,358.3,16485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16485,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,16485,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,16485,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,16486,0)
 ;;=D09.0^^61^775^44
 ;;^UTILITY(U,$J,358.3,16486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16486,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,16486,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,16486,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,16487,0)
 ;;=D06.9^^61^775^45
 ;;^UTILITY(U,$J,358.3,16487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16487,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,16487,1,4,0)
 ;;=4^D06.9
